Lantus(insulin glargine)
Abasaglar, Abasria, Basaglar, Lantus, Optisulin, Rezvoglar, Semglee, Soliqua, Suliqua, Toujeo (insulin glargine) is a protein pharmaceutical. Insulin glargine was first approved as Lantus on 2000-04-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Basaglar, Lantus, Rezvoglar, Semglee, Toujeo (discontinued: Basaglar, Lantus, Semglee)
CombinationsSoliqua
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin glargine
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| soliqua 100/33 | Biologic Licensing Application | 2025-06-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
| type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
| hyperglycemia | — | D006943 | R73.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
insulin glargine, Semglee, Biocon Biologics Inc. | |||
| 11/15/2022 | Interchangeable excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
712 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin glargine |
| INN | insulin glargine |
| Description | Insulin glargine recombinant |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 4IYD, 4IYF, 5VIZ |
| CAS-ID | 160337-95-1 |
| RxCUI | 274783 |
| ChEMBL ID | CHEMBL1201497 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00047 |
| UNII ID | 2ZM8CX04RZ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
Insulin glargine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,977 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
122,786 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use